Cardilax, Cartalax, Cardarine: three names, one dangerous mix-up

Three names that should never share a syringe

Here is the honest tension. Two of these compounds are nearly harmless and nearly useless. One of them caused cancer in multiple organs of two species and was abandoned by the company that built it. And the only thing reliably separating them, for a buyer reading a label, is a few letters that are easy to misread, mistype, or fake.

That is not a pedantic spelling complaint. In a market where the vial often does not match the label, a name you cannot pronounce with confidence is a name you cannot trust your body to. This post exists to keep three things apart that the gray market keeps smudging together.

Cartalax: thin evidence, low stakes

Cartalax is a real peptide. It is one of the Khavinson short peptide bioregulators, a very short sequence (reported as the tripeptide Ala-Glu-Asp, sometimes written as a four-amino-acid version) developed in Russia and marketed for cartilage and joints. It is the genuine third ingredient in some "Deadpool" blends, including the one sold by Nexaph.

On our scale, Cartalax earns an Evidence grade of E, theoretical. The case for it rests on cell-culture gene-expression work and one 2014 study in Bulletin of Experimental Biology and Medicine reporting restored cartilage structure in aged rats. The primary literature is published largely in Russian gerontology journals, with no human clinical trials behind it. Its Safety grade is C, thinly characterized. We have not seen alarming signals, but human exposure is small and the long-term data simply does not exist. Low evidence, low stakes. The honest summary is: probably does little, probably hurts little.

Cardarine (GW-501516): a flagged drug, not a peptide

Cardarine is a different kind of thing entirely. It is not a peptide. GW-501516 is a PPARδ receptor agonist, a small-molecule drug originally developed by GlaxoSmithKline and Ligand for metabolic and lipid disorders. It is frequently sold as if it were a SARM, which USADA explicitly notes is incorrect.

Here is why it carries our hardest warning. GSK ended its development, most sources place this around 2006 to 2007, after long-term carcinogenicity studies. According to the toxicology summary, the drug "caused cancer to develop rapidly in several organs" at 3 mg/kg/day in both mice and rats, with tumors reported across the liver, stomach, tongue, skin, bladder, ovaries, womb, and testes. The underlying data were presented as Society of Toxicology meeting abstracts in 2009 (Geiger and Newsholme), which is worth flagging honestly: these are conference presentations, not a peer-reviewed PubMed paper, and rodent carcinogenicity does not translate one-to-one to humans.

But the regulatory verdict is not ambiguous. WADA took the rare step of issuing a public alert warning athletes directly about the health risks. USADA states it "is not available anywhere as an approved medication and has no recognized therapeutic uses." On our scale, Cardarine is Evidence D (no human efficacy data) and Safety E. Flagged. Documented serious risk, no human safety floor, no legal medical use.

Why the spelling is the hazard

Now hold the two side by side. Cartalax: peptide, E/C, mostly harmless. Cardarine: PPARδ drug, D/E, with a carcinogenicity signal serious enough to earn a global anti-doping alert. The names are not close in chemistry. They are close on a label.

The confusion has a third leg, and it is the one our research kept hitting. The spelling "Cardilax" is not a peptide at all, it is an unrelated prescription anxiety tablet (alprazolam plus propranolol). So a single fuzzy "cardi-" string points at three completely different substances: a benign cartilage peptide, a cancer-flagged research drug, and a benzodiazepine combo. A buyer who wanted the first, typed the second, and got steered toward the third is not a hypothetical. It is the predictable failure mode of a market that sells by nickname.

This is precisely the gap Ground Truth exists to close. When the name on the vial is a meme reference or a near-homophone, the chemistry underneath it is doing none of the verifying for you.

The grounded takeaway

If you see "Cardilax" on a peptide product, treat it as a red flag and stop. The intended ingredient is almost certainly Cartalax, a real but barely-evidenced bioregulator, but the label has already failed its one job, which is telling you what is in the vial. And under no reading does the word mean Cardarine, a drug that should not be in a peptide stack at all.

The rule is simple and it generalizes past these three names: a compound you cannot reliably name is a compound you cannot reliably dose, source, or research. When you cannot name what is in the vial, there is no science underneath it, only a spelling you are trusting with your liver.